QuidelOrtho (NASDAQ:QDEL) Issues FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.070-2.570 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

QuidelOrtho Price Performance

QDEL stock traded down $1.08 during midday trading on Friday, reaching $40.57. 1,445,774 shares of the company's stock traded hands, compared to its average volume of 828,934. The company has a 50-day simple moving average of $43.41 and a two-hundred day simple moving average of $42.39. QuidelOrtho has a 1-year low of $29.74 and a 1-year high of $49.56. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -1.45 and a beta of 0.08. The company has a quick ratio of 0.81, a current ratio of 1.38 and a debt-to-equity ratio of 0.68.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. On average, analysts anticipate that QuidelOrtho will post 1.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on QDEL. William Blair reiterated a "market perform" rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. Royal Bank of Canada reduced their price target on QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a research report on Thursday. Citigroup raised QuidelOrtho from a "neutral" rating to a "buy" rating and raised their target price for the company from $44.00 to $50.00 in a report on Wednesday, December 11th. StockNews.com downgraded QuidelOrtho from a "buy" rating to a "hold" rating in a report on Saturday. Finally, UBS Group raised their target price on QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a report on Thursday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $51.20.

Insider Activity at QuidelOrtho

In other news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of QuidelOrtho stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $35.31, for a total value of $291,667,061.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian J. Blaser acquired 6,033 shares of the stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average cost of $41.42 per share, with a total value of $249,886.86. Following the completion of the transaction, the chief executive officer now owns 6,033 shares in the company, valued at approximately $249,886.86. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 1.00% of the stock is currently owned by company insiders.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.